5 completed, 2 recruiting. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Recruiting 2 |
Follow Cantargia AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunoprevention for High-risk Lung Lesions Nadunolimab - High-risk Lung Nodules | Phase 2 | Recruiting | Robert Samstein | 59 | 2026-05-21 | 2026-06-08 |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC Nadunolimab, Toripalimab - Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2025-12-01 | 2026-02-19 |
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. Carboplatin, Gemcitabine, Nadunolimab - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 117 | 2022-01-11 | 2026-05-27 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors CAN04 (nadunolimab), mFOLFOX, DTX - Advanced Solid Tumors, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 40 | 2021-09-22 | 2023-07-03 |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma CAN04, FOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Cantargia AB | 25 | 2021-07-19 | 2023-06-29 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors CAN04, Pembrolizumab, Carboplatin - Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma | Phase 1 | Completed | Cantargia AB | 19 | 2020-09-24 | 2023-07-14 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors CAN04, Cisplatin, Gemcitabine - Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Cantargia AB | 167 | 2017-09-19 | 2024-08-22 |
Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carboplatin (3) · Gemcitabine (3) · Cisplatin (2) · Pemetrexed (2) · 130-nm albumin-bound paclitaxel (1) · Docetaxel (1) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · folfirinox (1) · pembrolizumab (1) · toripalimab (1)
Spain (4) · United States (3) · France (2) · Austria (1) · Belgium (1) · Denmark (1) · Estonia (1) · Germany (1) · Latvia (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Sweden (1)
Ignacio Garcia-Ribas, MD, PhD (3) · Ahmad Awada, Professor (1) · Dan Feng, MD, PhD (1) · Robert M Samstein, MD, PhD (1) · Thomas Marron, MD, PhD (1)
PMID 34903842, PMID 40310569, PMID 40680438
2017 (1)